Are you perimenopausal? Are you interested in learning more about your metabolism, body composition, and exercise during the menopause transition? If so, you may be able to participate in a research study to understand the impact of muscle and exercise across perimenopause!

Do you ever notice that you feel more energized or alert when meeting new people and forming first impressions? Other times, a first meeting will rub you the wrong way and you may feel less attentive. If you've experienced one or both of these, you may wonder: What makes a good first impression? How do you know you want to become friends with someone? What information do we pay attention to when interacting with someone for the first time? Good questions! Neuroscience and psychology researchers wonder about the same things. Here at the Social Neuroscience and Health lab, we study how the brain and the immune system work together to influence our behaviors and experiences. The Friendship Pathways Study is a research project aiming to answer questions about how the brain and immune system communicate when meeting new people and forming friendships.

Have you been diagnosed with Lateralized Oropharyngeal Cancer . If so, you may be able to take part in a research study looking at the safety by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT) compared to the usual treatment when radiotherapy is given .

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Do you have pancreatic ductal adenocarcinoma that has come back after receiving standard therapy? If so, you may be able to participate in this gene therapy research study to learn more about using you own modified immune cells as possible treatment.

Have you been diagnosed with a B cell disease that has returned after your previous treatment or is not responding to your current treatment? If so, you might be able to take part in a study to see if a new treatment is safe and can help treat people with B-cell diseases.

Have you ever wondered what environmental toxins you are exposed to on a daily basis, and how it might affect your health? The STRIVE study is looking for volunteers who would like to provide blood, urine, and/or saliva, as well as home samples such as soil, dust, and/or water. In this study, we want to learn more about the environmental factors that contribute to advanced liver disease and liver cancer. We are looking for healthy volunteers and people with liver cirrhosis who live in either North Carolina or Georgia to take part.

Do you have Non-Small Cell Lung Cancer? Have you previously been treated with Osimertinib? If so, you may be eligible for a trial comparing osimertinib in combination with other medications to treat your lung cancer. Please reach out if you're interested!

Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.